SlideShare a Scribd company logo
1 of 18
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved
Cardinal Health
36th Annual JP Morgan Healthcare Conference
Mike Kaufmann
Chief Executive Officer
Monday, January 8, 2018
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
Forward-looking statements and GAAP reconciliation
Cautions Concerning Forward-Looking Statements
This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent
upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe,"
"will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or
guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results
to differ materially from those projected, anticipated or implied. These risks and uncertainties include competitive pressures in Cardinal
Health's various lines of business; the amount or rate of pharmaceutical price appreciation or deflation and the timing of and benefit from
generic pharmaceutical introductions; the ability to maintain the benefits from the generic sourcing venture with CVS Health; risks
associated with the recently completed acquisition of the Patient Recovery business, including the ability to retain the acquired businesses’
customer and employees, the ability to successfully integrate the acquired business into our operations and the ability to achieve the
expected synergies as well as accretion in earnings; the risk of non-renewal or a default under one or more key customer or supplier
arrangements or changes to the terms of or level of purchases under those arrangements; uncertainties with respect to the recently
enacted Tax Cuts and Jobs Act, including the ability to realize the benefits of, and mitigate the risks from the Act; changes in the distribution
patterns or reimbursement rates for health care products and services; the effects of any investigation or action by any regulatory authority,
including litigation related to opioid distribution. Cardinal Health is subject to additional risks and uncertainties described in Cardinal
Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This presentation reflects management's views as of
January 8, 2018. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-
looking statement. In addition, this presentation contains Non-GAAP financial measures. Cardinal Health provides definitions and
reconciliations of the differences between the Non-GAAP financial measures and their most directly comparable GAAP financial measures
in the Financial Appendix at the end of this presentation and at ir.cardinalhealth.com.
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
For those tasked with navigating the complexities of healthcare…
Cardinal Health brings
scaled solutions that
help our customers thrive
in a changing world.
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
Essential facts about Cardinal Health
A global, integrated healthcare products & services company
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
Essential facts about Cardinal Health
A global, integrated healthcare products & services company
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
Healthcare Trends
Care shifts to
more efficient
settings
Global
demand
swells
Precision
medicine
Healthcare
consumerism
Power of
generics and
breakthrough
innovation
Government’s
expanding
role
Mobile
connectivity
Value-based
care
Partnerships
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
1FY17 GAAP operating earnings $2,120M
2Attributable to Cardinal Health, Inc. FY17 GAAP diluted EPS $4.03
Please see appendix for GAAP to Non-GAAP reconciliations.
Revenue ($M)
non-GAAP Operating
Earnings1 ($M)
non-GAAP Diluted EPS2
$129,976
$2,769
$5.40
FY17 financial summary
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
1Q1FY18 GAAP operating earnings $262M
2Attributable to Cardinal Health, Inc. Q1FY18 GAAP diluted EPS $0.36
Please see appendix for GAAP to Non-GAAP reconciliations.
Revenue ($M)
non-GAAP Operating
Earnings1 ($M)
non-GAAP Diluted EPS2
$32,641
$610
$1.09
Q1FY18 financial summary
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
FY17 revenues of $116B
Pharmaceutical Medical
FY17 segment profit of $2.2B FY17 segment profit of $572M
FY17 revenues of $13.5B
Two financial reporting segments…
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
Acquisition of Medtronic’s Patient Recovery Business
Purchase price
Closed
Product Categories
$6.1B
July 2017
23
Manufacturing facilities
FY18 non-GAAP Diluted EPS1 Impact
FY19 non-GAAP Diluted EPS1 Impact
17
>$0.21
>$0.55
Annual Operational synergies exiting FY20 >$150M
1Attributable to Cardinal Health, Inc.
2Expected financial impact provided on April 18, 2017.
Please see appendix for GAAP to Non-GAAP definitions.
2
2
2
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
Patient Recovery Business Product Lines
Bandages, dressings,
underpads, adult briefs,
protective underwear
Sharps disposal containers,
hypodermic needles,
prefilled syringes
Compression devices,
anti-embolism stockings,
disposable lead wires
Enteral feeding pumps, sets,
tubes and access devices
Foam positioners,
delivery kits, OR essentials
Urology, collection systems
Open suction,
cardiothoracic drainage,
catheters
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
Enable a more efficient
way of bringing healthcare
to market
Optimize the process and
performance of healthcare
Connect clinicians and
patients for smarter
population management,
better patient wellness
Provide a comprehensive
healthcare product offering
Logistics
Solutions
Business
Solutions
Product
Solutions
Patient
Solutions
Cardinal Health goes to market with enterprise-wide
capabilities in four areas
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
Pharma
distribution
Med surg
distribution
Specialty
Nuclear
Consulting
3PL
services
Inventory
management
services
Generics
CAH
branded
products
OptiFrieght®
Surgical
kitting
Robust solutions for an existing customer
• One of the largest not-for-profit
healthcare providers
• $4B+ in revenues
• 10+ hospitals, long-term care
facilities, physician offices,
retail clinics and pharmacies,
and rehabilitation centers
services
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved
Cardinal Health
36th Annual JP Morgan Healthcare Conference
Mike Kaufmann
Chief Executive Officer
Monday, January 8, 2018
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
1For more information on these measures, refer to the Use of Non-GAAP Financial Measures and Definitions schedules
2Attributable to Cardinal Health, Inc.
3GAAP diluted EPS for the twelve months ended June 30, 2017 compared to the prior year period was favorably impacted by $0.39, which includes $0.26 due to change in the effective tax rate and $0.13 due to the change in
weighted average shares outstanding. The change in GAAP diluted EPS due to the effective tax rate is calculated as ((GAAP Earnings before Income Taxes for the current period times (one minus the current period GAAP
Effective Tax Rate)) minus (GAAP Earnings before Income Taxes for the current period times (one minus the prior period GAAP Effective Tax Rate))) divided by the current period weighted average shares outstanding. The
change in GAAP diluted EPS due to the weighted average shares outstanding is calculated as (GAAP Net Earnings for the current period divided by the current period weighted average shares outstanding) minus (GAAP Net
Earnings for the current period divided by the prior period weighted average shares outstanding).
4Non-GAAP diluted EPS for the twelve months ended June 30, 2017 compared to the prior year period was favorably impacted by $0.44, which includes $0.27 due to change in the effective tax rate and $0.17 due to the change in
weighted average shares outstanding. The change in Non-GAAP diluted EPS due to the effective tax rate is calculated as ((Non-GAAP Earnings before Income Taxes for the current period times (one minus the current period
Non-GAAP Effective Tax Rate)) minus (Non-GAAP Earnings before Income Tax for the current period times (one minus the prior period Non-GAAP Effective Tax Rate))) divided by the current period weighted average shares
outstanding. The change in Non-GAAP diluted EPS due to the weighted average shares outstanding is calculated as (Non-GAAP Net Earnings for the current period divided by the current period weighted average shares
outstanding) minus (Non-GAAP Net Earnings for the current period divided by the prior period weighted average shares outstanding).
The sum of the components may not equal the total due to rounding.
We generally apply varying tax rates depending on the item’s nature and tax jurisdiction where it is incurred.
There were no losses on extinguishment of debt during the periods presented.
Operating Provision for Net Diluted
Operating Earnings Earnings Before Income Net Earnings2
Diluted EPS2
Earnings Growth Rate Income Taxes Taxes Earnings2
Growth Rate EPS2
Growth Rate
(in millions, except per common share amounts)
GAAP 2,120$ (14)% 1,924$ 630$ 1,288$ (10)% 4.03$ (7)%
Restructuring and employee severance 56 56 20 36 0.11
Amortization and other acquisition-related costs 527 527 165 362 1.13
Impairments and (gain)/loss on disposal of assets 18 18 6 12 0.04
Litigation (recoveries)/charges, net 48 48 19 29 0.09
Loss on extinguishment of debt - - - - -
Non-GAAP 2,769$ (4)% 2,572$ 839$ 1,727$ (0)% 5.40$ 3 %
GAAP 2,459$ 14 % 2,276$ 845$ 1,427$ 18 % 4.32$ 20 %
LIFO charges/(credits) - - - - -
Restructuring and employee severance 25 25 9 16 0.05
Amortization and other acquisition-related costs 459 459 143 316 0.96
Impairments and (gain)/loss on disposal of assets 21 21 6 15 0.04
Litigation (recoveries)/charges, net (69) (69) (27) (42) (0.13)
Non-GAAP 2,895$ 17 % 2,711$ 976$ 1,732$ 18 % 5.24$ 20 %
Fiscal Year 2016
Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation1
Fiscal Year 2017
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
1For more information on these measures, refer to the Use of Non-GAAP Financial Measures and Definitions schedules
2Attributable to Cardinal Health, Inc.
The sum of the components may not equal the total due to rounding.
We generally apply varying tax rates depending on the item’s nature and tax jurisdiction where it is incurred.
There were no losses on extinguishment of debt during the First Quarter 2017.
Operating Provision for Net Diluted
Operating Earnings Earnings Before Income Net Earnings2 Diluted EPS2
Earnings Growth Rate Income Taxes Taxes Earnings2 Growth Rate EPS2 Growth Rate
(in millions, except per common share amounts)
GAAP 262$ (51)% 178$ 61$ 115$ (63)% 0.36$ (63)%
Restructuring and employee severance 132 132 47 85 0.27
Amortization and other acquisition-related costs 183 183 58 125 0.40
Impairments and (gain)/loss on disposal of assets 1 1 - 1 -
Litigation (recoveries)/charges, net 32 32 13 19 0.06
Loss on extinguishment of debt - 1 1 - -
Non-GAAP 610$ (9)% 527$ 180$ 346$ (13)% 1.09$ (12)%
GAAP 535$ (14)% 494$ 184$ 309$ (19)% 0.96$ (17)%
Restructuring and employee severance 9 9 4 5 0.02
Amortization and other acquisition-related costs 122 122 40 82 0.25
Impairments and (gain)/loss on disposal of assets 3 3 1 2 0.01
Litigation (recoveries)/charges, net 1 1 - 1 -
Non-GAAP 669$ (9)% 629$ 229$ 399$ (13)% 1.24$ (10)%
Cardinal Health, Inc. and Subsidiaries
GAAP / Non-GAAP Reconciliation1
First Quarter 2018
First Quarter 2017
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
Cardinal Health, Inc. and Subsidiaries
Forward Looking non-GAAP Measures
In this presentation, the Company presents forward-looking non-GAAP EPS and may present forward-looking non-GAAP ETR metrics. The Company does
not provide EPS or ETR outlook, which are the most directly comparable GAAP measure to non-GAAP EPS and non-GAAP ETR, respectively, because
changes in the items that the Company excludes from these non-GAAP measures can be dependent on future events that are less capable of being
controlled or reliably predicted by management and are not part of the Company’s routine operating activities. Additionally, due to their unpredictability,
management does not forecast many of the excluded items for internal use and therefore cannot create or rely on an EPS or ETR outlook.
The timing and amount of any of the excluded items could significantly impact the actual EPS and ETR metrics. Over the past five fiscal years, the excluded
items have lowered the Company’s EPS from $0.47 to $2.76, which includes a goodwill impairment charge of $2.32 per share related to our Nuclear
Pharmacy Services division that we recognized in fiscal 2013.
© Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved.
1
The inventories of the Company's core pharmaceutical distribution facilities in the Pharmaceutical segment are valued at the lower of cost, using the LIFO method, or market. These charges or credits are included in cost of products sold, and represent
changes in the Company's LIFO inventory reserve.
2
Programs by which the Company fundamentally changes its operations such as closing and consolidating facilities, moving manufacturing of a product to another location, production or business process sourcing, employee severance (including
rationalizing headcount or other significant changes in personnel), and realigning operations (including realignment of the management structure of a business unit in response to changing market conditions).
3
Costs that consist primarily of amortization of acquisition-related intangible assets, transaction costs, integration costs, and changes in the fair value of contingent consideration obligations.
4
Asset impairments and (gains)/losses from the disposal of assets not eligible to be classified as discontinued operations are classified within impairments and (gain)/loss on disposal of assets within the condensed consolidated statements of earnings.
5
Loss contingencies related to litigation and regulatory matters and income from favorable resolution of legal matters.
6
Charges related to the make-whole premium on the redemption of notes.
Cardinal Health, Inc. and Subsidiaries
Definitions
Debt: long-term obligations plus short-term borrowings.
Debt to Total Capital: debt divided by (debt plus total Cardinal Health, Inc. shareholders’ equity).
Interest and Other, net: other (income)/expense, net plus interest expense, net.
Net Debt: a Non-GAAP measure defined as debt minus (cash and equivalents).
Net Debt to Capital: a Non-GAAP measure defined as net debt divided by (net debt plus total Cardinal Health, Inc. shareholders’ equity).
Non-GAAP Diluted EPS attributable to Cardinal Health, Inc. or "Non-GAAP Diluted EPS" or "Non-GAAP Diluted Earnings Per Share": non-GAAP net earnings attributable to Cardinal
Health, Inc. divided by diluted weighted-average shares outstanding.
Non-GAAP Diluted EPS from continuing operations: non-GAAP earnings from continuing operations divided by diluted weighted-average shares outstanding.
Non-GAAP Effective Tax Rate: (provision for income taxes adjusted for (1) LIFO charges/(credits)
1
, (2) restructuring and employee severance
2
, (3) amortization and other acquisition-related
costs
3
, (4) impairments and (gain)/loss on disposal of assets
4
, (5) litigation (recoveries)/charges, net
5
, and (6) loss on extinguishment of debt
6
) divided by (earnings before income taxes
adjusted for the same six items).
Non-GAAP Gross Margin: Gross margin excluding LIFO charges/(credits).

More Related Content

What's hot

Cardinal Health Q1 FY 2017 Earnings Presentation
Cardinal Health Q1 FY 2017 Earnings PresentationCardinal Health Q1 FY 2017 Earnings Presentation
Cardinal Health Q1 FY 2017 Earnings PresentationCardinal_Health
 
3Q FY2017 Earnings Presentation
3Q FY2017 Earnings Presentation3Q FY2017 Earnings Presentation
3Q FY2017 Earnings PresentationCardinal_Health
 
Cah investorand analystday dec10.2013
Cah investorand analystday dec10.2013Cah investorand analystday dec10.2013
Cah investorand analystday dec10.2013Cardinal_Health
 
J.P. Morgan 32nd Annual Healthcare Conference Presentation
J.P. Morgan 32nd Annual Healthcare Conference PresentationJ.P. Morgan 32nd Annual Healthcare Conference Presentation
J.P. Morgan 32nd Annual Healthcare Conference PresentationCardinal_Health
 
Q4 Earnings Presentation
Q4 Earnings PresentationQ4 Earnings Presentation
Q4 Earnings PresentationCardinal_Health
 
Q2 fy17 cah earnings presentation
Q2 fy17 cah earnings presentationQ2 fy17 cah earnings presentation
Q2 fy17 cah earnings presentationCardinal_Health
 
Cardinal Health Q3 FY 2016 Earnings Presentation
Cardinal Health Q3 FY 2016 Earnings PresentationCardinal Health Q3 FY 2016 Earnings Presentation
Cardinal Health Q3 FY 2016 Earnings PresentationCardinal_Health
 
Cardinal Health Q2 FY 2016 Earnings Presentation
Cardinal Health Q2 FY 2016 Earnings PresentationCardinal Health Q2 FY 2016 Earnings Presentation
Cardinal Health Q2 FY 2016 Earnings PresentationCardinal_Health
 
Q3 fy15 earnings deck final
Q3 fy15 earnings deck finalQ3 fy15 earnings deck final
Q3 fy15 earnings deck finalCardinal_Health
 
Q2 fy15 earnings presentation
Q2 fy15 earnings presentationQ2 fy15 earnings presentation
Q2 fy15 earnings presentationCardinal_Health
 
Cardinal Health Dublin Day Presentation
Cardinal Health Dublin Day PresentationCardinal Health Dublin Day Presentation
Cardinal Health Dublin Day PresentationCardinal_Health
 
J.P. Morgan 34th Annual Healthcare Conference Presentation
J.P. Morgan 34th Annual Healthcare Conference PresentationJ.P. Morgan 34th Annual Healthcare Conference Presentation
J.P. Morgan 34th Annual Healthcare Conference PresentationCardinal_Health
 
Q1 fy16 earnings deck final
Q1 fy16 earnings deck finalQ1 fy16 earnings deck final
Q1 fy16 earnings deck finalCardinal_Health
 
J.P. Morgan 33rd Annual Healthcare Conference
J.P. Morgan 33rd Annual Healthcare ConferenceJ.P. Morgan 33rd Annual Healthcare Conference
J.P. Morgan 33rd Annual Healthcare ConferenceCardinal_Health
 
Cardinal Health 2015 Investor & Analyst Day
Cardinal Health 2015 Investor & Analyst DayCardinal Health 2015 Investor & Analyst Day
Cardinal Health 2015 Investor & Analyst DayCardinal_Health
 
2015 cah-annl sharemtgpres-115_final
2015 cah-annl sharemtgpres-115_final2015 cah-annl sharemtgpres-115_final
2015 cah-annl sharemtgpres-115_finalCardinal_Health
 
Cah inv pres 3 3 15 cowen final
Cah inv pres 3 3 15 cowen finalCah inv pres 3 3 15 cowen final
Cah inv pres 3 3 15 cowen finalCardinal_Health
 

What's hot (20)

Cardinal Health Q1 FY 2017 Earnings Presentation
Cardinal Health Q1 FY 2017 Earnings PresentationCardinal Health Q1 FY 2017 Earnings Presentation
Cardinal Health Q1 FY 2017 Earnings Presentation
 
3Q FY2017 Earnings Presentation
3Q FY2017 Earnings Presentation3Q FY2017 Earnings Presentation
3Q FY2017 Earnings Presentation
 
Cah investorand analystday dec10.2013
Cah investorand analystday dec10.2013Cah investorand analystday dec10.2013
Cah investorand analystday dec10.2013
 
J.P. Morgan 32nd Annual Healthcare Conference Presentation
J.P. Morgan 32nd Annual Healthcare Conference PresentationJ.P. Morgan 32nd Annual Healthcare Conference Presentation
J.P. Morgan 32nd Annual Healthcare Conference Presentation
 
Q4 Earnings Presentation
Q4 Earnings PresentationQ4 Earnings Presentation
Q4 Earnings Presentation
 
Q2 fy17 cah earnings presentation
Q2 fy17 cah earnings presentationQ2 fy17 cah earnings presentation
Q2 fy17 cah earnings presentation
 
Q4 fy15 earnings deck
Q4 fy15 earnings deckQ4 fy15 earnings deck
Q4 fy15 earnings deck
 
Cardinal Health Q3 FY 2016 Earnings Presentation
Cardinal Health Q3 FY 2016 Earnings PresentationCardinal Health Q3 FY 2016 Earnings Presentation
Cardinal Health Q3 FY 2016 Earnings Presentation
 
Cardinal Health Q2 FY 2016 Earnings Presentation
Cardinal Health Q2 FY 2016 Earnings PresentationCardinal Health Q2 FY 2016 Earnings Presentation
Cardinal Health Q2 FY 2016 Earnings Presentation
 
Q3 fy15 earnings deck final
Q3 fy15 earnings deck finalQ3 fy15 earnings deck final
Q3 fy15 earnings deck final
 
Q2 fy15 earnings presentation
Q2 fy15 earnings presentationQ2 fy15 earnings presentation
Q2 fy15 earnings presentation
 
Cardinal Health Dublin Day Presentation
Cardinal Health Dublin Day PresentationCardinal Health Dublin Day Presentation
Cardinal Health Dublin Day Presentation
 
J.P. Morgan 34th Annual Healthcare Conference Presentation
J.P. Morgan 34th Annual Healthcare Conference PresentationJ.P. Morgan 34th Annual Healthcare Conference Presentation
J.P. Morgan 34th Annual Healthcare Conference Presentation
 
Q1 fy16 earnings deck final
Q1 fy16 earnings deck finalQ1 fy16 earnings deck final
Q1 fy16 earnings deck final
 
J.P. Morgan 33rd Annual Healthcare Conference
J.P. Morgan 33rd Annual Healthcare ConferenceJ.P. Morgan 33rd Annual Healthcare Conference
J.P. Morgan 33rd Annual Healthcare Conference
 
Cardinal Health 2015 Investor & Analyst Day
Cardinal Health 2015 Investor & Analyst DayCardinal Health 2015 Investor & Analyst Day
Cardinal Health 2015 Investor & Analyst Day
 
2015 cah-annl sharemtgpres-115_final
2015 cah-annl sharemtgpres-115_final2015 cah-annl sharemtgpres-115_final
2015 cah-annl sharemtgpres-115_final
 
Q3 fy14 earnings deck
Q3 fy14 earnings deckQ3 fy14 earnings deck
Q3 fy14 earnings deck
 
Q3 fy14 earnings deck
Q3 fy14 earnings deckQ3 fy14 earnings deck
Q3 fy14 earnings deck
 
Cah inv pres 3 3 15 cowen final
Cah inv pres 3 3 15 cowen finalCah inv pres 3 3 15 cowen final
Cah inv pres 3 3 15 cowen final
 

Similar to Jp morgan conf final

35th Annual J.P. Morgan Healthcare Conference Presentation
35th Annual J.P. Morgan Healthcare Conference Presentation35th Annual J.P. Morgan Healthcare Conference Presentation
35th Annual J.P. Morgan Healthcare Conference PresentationCardinal_Health
 
Q1 2018 earnings charts final
Q1 2018 earnings charts   finalQ1 2018 earnings charts   final
Q1 2018 earnings charts finalpfizer_ir
 
Credit suisse-presentation-nov-8-final
Credit suisse-presentation-nov-8-finalCredit suisse-presentation-nov-8-final
Credit suisse-presentation-nov-8-finalCardinal_Health
 
Cardinal Health Q4 FY 2016 Earnings Presentation
Cardinal Health Q4 FY 2016 Earnings PresentationCardinal Health Q4 FY 2016 Earnings Presentation
Cardinal Health Q4 FY 2016 Earnings PresentationCardinal_Health
 
Final dplo q1 2018 operating results ir deck
Final dplo q1 2018 operating results ir deckFinal dplo q1 2018 operating results ir deck
Final dplo q1 2018 operating results ir deckDiplomatIR
 
Dplo raymond james ir deck (3)
Dplo  raymond james ir deck (3)Dplo  raymond james ir deck (3)
Dplo raymond james ir deck (3)DiplomatIR
 
Dplo q1 2018 operating results ir deck (1)
Dplo q1 2018 operating results ir deck (1)Dplo q1 2018 operating results ir deck (1)
Dplo q1 2018 operating results ir deck (1)DiplomatIR
 
Q1 fy15 earnings presentation final w schedules
Q1 fy15 earnings presentation final w schedulesQ1 fy15 earnings presentation final w schedules
Q1 fy15 earnings presentation final w schedulesCardinal_Health
 
Q4 2017-earnings-charts-final
Q4 2017-earnings-charts-finalQ4 2017-earnings-charts-final
Q4 2017-earnings-charts-finalpfizer_ir
 
Raymond james presentation 03 04 2014
Raymond james presentation 03 04 2014Raymond james presentation 03 04 2014
Raymond james presentation 03 04 2014Cardinal_Health
 
CanniMed Therapeutics Inc. Investor Deck February 2017
CanniMed Therapeutics Inc. Investor Deck February 2017CanniMed Therapeutics Inc. Investor Deck February 2017
CanniMed Therapeutics Inc. Investor Deck February 2017CannimedTherapeutics
 
Cardinal Health 2016 Annual Shareholder Meeting Presentation
Cardinal Health 2016 Annual Shareholder Meeting PresentationCardinal Health 2016 Annual Shareholder Meeting Presentation
Cardinal Health 2016 Annual Shareholder Meeting PresentationCardinal_Health
 
Pfizer Q1 2017 Earnings Charts
Pfizer Q1 2017 Earnings ChartsPfizer Q1 2017 Earnings Charts
Pfizer Q1 2017 Earnings Chartspfizer_ir
 
AMN-Investor-Presentation-May-2022-FINAL.pdf
AMN-Investor-Presentation-May-2022-FINAL.pdfAMN-Investor-Presentation-May-2022-FINAL.pdf
AMN-Investor-Presentation-May-2022-FINAL.pdfMOHAMMED YASER HUSSAIN
 
Agility health investor presentation - investor tab 07.18.16
Agility health   investor presentation - investor tab 07.18.16Agility health   investor presentation - investor tab 07.18.16
Agility health investor presentation - investor tab 07.18.16AgilityHealth
 

Similar to Jp morgan conf final (16)

35th Annual J.P. Morgan Healthcare Conference Presentation
35th Annual J.P. Morgan Healthcare Conference Presentation35th Annual J.P. Morgan Healthcare Conference Presentation
35th Annual J.P. Morgan Healthcare Conference Presentation
 
Q1 2018 earnings charts final
Q1 2018 earnings charts   finalQ1 2018 earnings charts   final
Q1 2018 earnings charts final
 
Credit suisse-presentation-nov-8-final
Credit suisse-presentation-nov-8-finalCredit suisse-presentation-nov-8-final
Credit suisse-presentation-nov-8-final
 
Cardinal Health Q4 FY 2016 Earnings Presentation
Cardinal Health Q4 FY 2016 Earnings PresentationCardinal Health Q4 FY 2016 Earnings Presentation
Cardinal Health Q4 FY 2016 Earnings Presentation
 
Final dplo q1 2018 operating results ir deck
Final dplo q1 2018 operating results ir deckFinal dplo q1 2018 operating results ir deck
Final dplo q1 2018 operating results ir deck
 
Dplo raymond james ir deck (3)
Dplo  raymond james ir deck (3)Dplo  raymond james ir deck (3)
Dplo raymond james ir deck (3)
 
Dplo q1 2018 operating results ir deck (1)
Dplo q1 2018 operating results ir deck (1)Dplo q1 2018 operating results ir deck (1)
Dplo q1 2018 operating results ir deck (1)
 
Q1 fy15 earnings presentation final w schedules
Q1 fy15 earnings presentation final w schedulesQ1 fy15 earnings presentation final w schedules
Q1 fy15 earnings presentation final w schedules
 
Q4 2017-earnings-charts-final
Q4 2017-earnings-charts-finalQ4 2017-earnings-charts-final
Q4 2017-earnings-charts-final
 
Raymond james presentation 03 04 2014
Raymond james presentation 03 04 2014Raymond james presentation 03 04 2014
Raymond james presentation 03 04 2014
 
CanniMed Therapeutics Inc. Investor Deck February 2017
CanniMed Therapeutics Inc. Investor Deck February 2017CanniMed Therapeutics Inc. Investor Deck February 2017
CanniMed Therapeutics Inc. Investor Deck February 2017
 
Cardinal Health 2016 Annual Shareholder Meeting Presentation
Cardinal Health 2016 Annual Shareholder Meeting PresentationCardinal Health 2016 Annual Shareholder Meeting Presentation
Cardinal Health 2016 Annual Shareholder Meeting Presentation
 
Pfizer Q1 2017 Earnings Charts
Pfizer Q1 2017 Earnings ChartsPfizer Q1 2017 Earnings Charts
Pfizer Q1 2017 Earnings Charts
 
AMN-Investor-Presentation-May-2022-FINAL.pdf
AMN-Investor-Presentation-May-2022-FINAL.pdfAMN-Investor-Presentation-May-2022-FINAL.pdf
AMN-Investor-Presentation-May-2022-FINAL.pdf
 
Cah acquires hdg
Cah acquires hdgCah acquires hdg
Cah acquires hdg
 
Agility health investor presentation - investor tab 07.18.16
Agility health   investor presentation - investor tab 07.18.16Agility health   investor presentation - investor tab 07.18.16
Agility health investor presentation - investor tab 07.18.16
 

More from Cardinal_Health

Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)Cardinal_Health
 
Cah presentation updated 4.19.17
Cah presentation updated 4.19.17Cah presentation updated 4.19.17
Cah presentation updated 4.19.17Cardinal_Health
 
Cah presentation patient productacquisition
Cah presentation patient productacquisitionCah presentation patient productacquisition
Cah presentation patient productacquisitionCardinal_Health
 
Dublin day presentation (1)
Dublin day presentation (1)Dublin day presentation (1)
Dublin day presentation (1)Cardinal_Health
 
2015 cah annl sharemtgpres 11.4
2015 cah annl sharemtgpres 11.42015 cah annl sharemtgpres 11.4
2015 cah annl sharemtgpres 11.4Cardinal_Health
 

More from Cardinal_Health (6)

Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)
 
Cah presentation updated 4.19.17
Cah presentation updated 4.19.17Cah presentation updated 4.19.17
Cah presentation updated 4.19.17
 
Cah presentation patient productacquisition
Cah presentation patient productacquisitionCah presentation patient productacquisition
Cah presentation patient productacquisition
 
Dublin day presentation (1)
Dublin day presentation (1)Dublin day presentation (1)
Dublin day presentation (1)
 
2015 cah annl sharemtgpres 11.4
2015 cah annl sharemtgpres 11.42015 cah annl sharemtgpres 11.4
2015 cah annl sharemtgpres 11.4
 
Cah inv pres bofa_final
Cah inv pres bofa_finalCah inv pres bofa_final
Cah inv pres bofa_final
 

Recently uploaded

一比一原版(UofG毕业证书)圭尔夫大学毕业证成绩单原件一模一样
一比一原版(UofG毕业证书)圭尔夫大学毕业证成绩单原件一模一样一比一原版(UofG毕业证书)圭尔夫大学毕业证成绩单原件一模一样
一比一原版(UofG毕业证书)圭尔夫大学毕业证成绩单原件一模一样dyuozua
 
Camil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdfCamil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdfCAMILRI
 
0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGOR
0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGOR0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGOR
0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGORjualobat34
 
皇后大学毕业证
皇后大学毕业证皇后大学毕业证
皇后大学毕业证dyuozua
 
Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024CollectiveMining1
 
一比一原版(Acadia毕业证书)加拿大阿卡迪亚大学毕业证学历认证可查认证
一比一原版(Acadia毕业证书)加拿大阿卡迪亚大学毕业证学历认证可查认证一比一原版(Acadia毕业证书)加拿大阿卡迪亚大学毕业证学历认证可查认证
一比一原版(Acadia毕业证书)加拿大阿卡迪亚大学毕业证学历认证可查认证xzxvi5zp
 
Western Copper and Gold - May 2024 Presentation
Western Copper and Gold - May 2024 PresentationWestern Copper and Gold - May 2024 Presentation
Western Copper and Gold - May 2024 PresentationPaul West-Sells
 
一比一原版(ArtEZ毕业证书)ArtEZ艺术学院毕业证成绩单原件一模一样
一比一原版(ArtEZ毕业证书)ArtEZ艺术学院毕业证成绩单原件一模一样一比一原版(ArtEZ毕业证书)ArtEZ艺术学院毕业证成绩单原件一模一样
一比一原版(ArtEZ毕业证书)ArtEZ艺术学院毕业证成绩单原件一模一样dyuozua
 
AMG Quarterly Investor Presentation May 2024
AMG Quarterly Investor Presentation May 2024AMG Quarterly Investor Presentation May 2024
AMG Quarterly Investor Presentation May 2024gstubel
 
Financial Results for the Fiscal Year Ended March 2024
Financial Results for the Fiscal Year Ended March 2024Financial Results for the Fiscal Year Ended March 2024
Financial Results for the Fiscal Year Ended March 2024KDDI
 
一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样
一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样
一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样dyuozua
 
Corporate Presentation Probe Canaccord Conference 2024.pdf
Corporate Presentation Probe Canaccord Conference 2024.pdfCorporate Presentation Probe Canaccord Conference 2024.pdf
Corporate Presentation Probe Canaccord Conference 2024.pdfProbe Gold
 
Teekay Tankers Q1-24 Earnings Presentation
Teekay Tankers Q1-24 Earnings PresentationTeekay Tankers Q1-24 Earnings Presentation
Teekay Tankers Q1-24 Earnings PresentationTeekay Tankers Ltd
 
BofA Securities GMM and Steel Conference
BofA Securities GMM and Steel ConferenceBofA Securities GMM and Steel Conference
BofA Securities GMM and Steel ConferenceTeckResourcesLtd
 
一比一原版(USYD毕业证书)悉尼大学毕业证成绩单原件一模一样
一比一原版(USYD毕业证书)悉尼大学毕业证成绩单原件一模一样一比一原版(USYD毕业证书)悉尼大学毕业证成绩单原件一模一样
一比一原版(USYD毕业证书)悉尼大学毕业证成绩单原件一模一样dyuozua
 
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024Osisko Gold Royalties Ltd
 
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...Klinik kandungan
 
Teck Sustainability Leadership, April 26, 2024
Teck Sustainability Leadership, April 26, 2024Teck Sustainability Leadership, April 26, 2024
Teck Sustainability Leadership, April 26, 2024TeckResourcesLtd
 

Recently uploaded (20)

一比一原版(UofG毕业证书)圭尔夫大学毕业证成绩单原件一模一样
一比一原版(UofG毕业证书)圭尔夫大学毕业证成绩单原件一模一样一比一原版(UofG毕业证书)圭尔夫大学毕业证成绩单原件一模一样
一比一原版(UofG毕业证书)圭尔夫大学毕业证成绩单原件一模一样
 
Camil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdfCamil Institutional Presentation_Mai24.pdf
Camil Institutional Presentation_Mai24.pdf
 
0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGOR
0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGOR0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGOR
0838*4800*7379 JUAL OBAT ABORSI CYTOTEC BOGOR
 
SME IPO Opportunity and Trends of May 2024
SME IPO Opportunity and Trends of May 2024SME IPO Opportunity and Trends of May 2024
SME IPO Opportunity and Trends of May 2024
 
皇后大学毕业证
皇后大学毕业证皇后大学毕业证
皇后大学毕业证
 
Osisko Gold Royalties Ltd - Q1 2024 Results
Osisko Gold Royalties Ltd - Q1 2024 ResultsOsisko Gold Royalties Ltd - Q1 2024 Results
Osisko Gold Royalties Ltd - Q1 2024 Results
 
Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024
 
一比一原版(Acadia毕业证书)加拿大阿卡迪亚大学毕业证学历认证可查认证
一比一原版(Acadia毕业证书)加拿大阿卡迪亚大学毕业证学历认证可查认证一比一原版(Acadia毕业证书)加拿大阿卡迪亚大学毕业证学历认证可查认证
一比一原版(Acadia毕业证书)加拿大阿卡迪亚大学毕业证学历认证可查认证
 
Western Copper and Gold - May 2024 Presentation
Western Copper and Gold - May 2024 PresentationWestern Copper and Gold - May 2024 Presentation
Western Copper and Gold - May 2024 Presentation
 
一比一原版(ArtEZ毕业证书)ArtEZ艺术学院毕业证成绩单原件一模一样
一比一原版(ArtEZ毕业证书)ArtEZ艺术学院毕业证成绩单原件一模一样一比一原版(ArtEZ毕业证书)ArtEZ艺术学院毕业证成绩单原件一模一样
一比一原版(ArtEZ毕业证书)ArtEZ艺术学院毕业证成绩单原件一模一样
 
AMG Quarterly Investor Presentation May 2024
AMG Quarterly Investor Presentation May 2024AMG Quarterly Investor Presentation May 2024
AMG Quarterly Investor Presentation May 2024
 
Financial Results for the Fiscal Year Ended March 2024
Financial Results for the Fiscal Year Ended March 2024Financial Results for the Fiscal Year Ended March 2024
Financial Results for the Fiscal Year Ended March 2024
 
一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样
一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样
一比一原版(YU毕业证书)约克大学毕业证成绩单原件一模一样
 
Corporate Presentation Probe Canaccord Conference 2024.pdf
Corporate Presentation Probe Canaccord Conference 2024.pdfCorporate Presentation Probe Canaccord Conference 2024.pdf
Corporate Presentation Probe Canaccord Conference 2024.pdf
 
Teekay Tankers Q1-24 Earnings Presentation
Teekay Tankers Q1-24 Earnings PresentationTeekay Tankers Q1-24 Earnings Presentation
Teekay Tankers Q1-24 Earnings Presentation
 
BofA Securities GMM and Steel Conference
BofA Securities GMM and Steel ConferenceBofA Securities GMM and Steel Conference
BofA Securities GMM and Steel Conference
 
一比一原版(USYD毕业证书)悉尼大学毕业证成绩单原件一模一样
一比一原版(USYD毕业证书)悉尼大学毕业证成绩单原件一模一样一比一原版(USYD毕业证书)悉尼大学毕业证成绩单原件一模一样
一比一原版(USYD毕业证书)悉尼大学毕业证成绩单原件一模一样
 
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
Osisko Gold Royalties Ltd - Corporate Presentation, May 2024
 
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
Jual obat aborsi Tawangmangu ( 085657271886 ) Cytote pil telat bulan penggugu...
 
Teck Sustainability Leadership, April 26, 2024
Teck Sustainability Leadership, April 26, 2024Teck Sustainability Leadership, April 26, 2024
Teck Sustainability Leadership, April 26, 2024
 

Jp morgan conf final

  • 1. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved Cardinal Health 36th Annual JP Morgan Healthcare Conference Mike Kaufmann Chief Executive Officer Monday, January 8, 2018
  • 2. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. Forward-looking statements and GAAP reconciliation Cautions Concerning Forward-Looking Statements This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include competitive pressures in Cardinal Health's various lines of business; the amount or rate of pharmaceutical price appreciation or deflation and the timing of and benefit from generic pharmaceutical introductions; the ability to maintain the benefits from the generic sourcing venture with CVS Health; risks associated with the recently completed acquisition of the Patient Recovery business, including the ability to retain the acquired businesses’ customer and employees, the ability to successfully integrate the acquired business into our operations and the ability to achieve the expected synergies as well as accretion in earnings; the risk of non-renewal or a default under one or more key customer or supplier arrangements or changes to the terms of or level of purchases under those arrangements; uncertainties with respect to the recently enacted Tax Cuts and Jobs Act, including the ability to realize the benefits of, and mitigate the risks from the Act; changes in the distribution patterns or reimbursement rates for health care products and services; the effects of any investigation or action by any regulatory authority, including litigation related to opioid distribution. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This presentation reflects management's views as of January 8, 2018. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward- looking statement. In addition, this presentation contains Non-GAAP financial measures. Cardinal Health provides definitions and reconciliations of the differences between the Non-GAAP financial measures and their most directly comparable GAAP financial measures in the Financial Appendix at the end of this presentation and at ir.cardinalhealth.com.
  • 3. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. For those tasked with navigating the complexities of healthcare… Cardinal Health brings scaled solutions that help our customers thrive in a changing world.
  • 4. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. Essential facts about Cardinal Health A global, integrated healthcare products & services company
  • 5. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. Essential facts about Cardinal Health A global, integrated healthcare products & services company
  • 6. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. Healthcare Trends Care shifts to more efficient settings Global demand swells Precision medicine Healthcare consumerism Power of generics and breakthrough innovation Government’s expanding role Mobile connectivity Value-based care Partnerships
  • 7. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. 1FY17 GAAP operating earnings $2,120M 2Attributable to Cardinal Health, Inc. FY17 GAAP diluted EPS $4.03 Please see appendix for GAAP to Non-GAAP reconciliations. Revenue ($M) non-GAAP Operating Earnings1 ($M) non-GAAP Diluted EPS2 $129,976 $2,769 $5.40 FY17 financial summary
  • 8. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. 1Q1FY18 GAAP operating earnings $262M 2Attributable to Cardinal Health, Inc. Q1FY18 GAAP diluted EPS $0.36 Please see appendix for GAAP to Non-GAAP reconciliations. Revenue ($M) non-GAAP Operating Earnings1 ($M) non-GAAP Diluted EPS2 $32,641 $610 $1.09 Q1FY18 financial summary
  • 9. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. FY17 revenues of $116B Pharmaceutical Medical FY17 segment profit of $2.2B FY17 segment profit of $572M FY17 revenues of $13.5B Two financial reporting segments…
  • 10. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. Acquisition of Medtronic’s Patient Recovery Business Purchase price Closed Product Categories $6.1B July 2017 23 Manufacturing facilities FY18 non-GAAP Diluted EPS1 Impact FY19 non-GAAP Diluted EPS1 Impact 17 >$0.21 >$0.55 Annual Operational synergies exiting FY20 >$150M 1Attributable to Cardinal Health, Inc. 2Expected financial impact provided on April 18, 2017. Please see appendix for GAAP to Non-GAAP definitions. 2 2 2
  • 11. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. Patient Recovery Business Product Lines Bandages, dressings, underpads, adult briefs, protective underwear Sharps disposal containers, hypodermic needles, prefilled syringes Compression devices, anti-embolism stockings, disposable lead wires Enteral feeding pumps, sets, tubes and access devices Foam positioners, delivery kits, OR essentials Urology, collection systems Open suction, cardiothoracic drainage, catheters
  • 12. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. Enable a more efficient way of bringing healthcare to market Optimize the process and performance of healthcare Connect clinicians and patients for smarter population management, better patient wellness Provide a comprehensive healthcare product offering Logistics Solutions Business Solutions Product Solutions Patient Solutions Cardinal Health goes to market with enterprise-wide capabilities in four areas
  • 13. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. Pharma distribution Med surg distribution Specialty Nuclear Consulting 3PL services Inventory management services Generics CAH branded products OptiFrieght® Surgical kitting Robust solutions for an existing customer • One of the largest not-for-profit healthcare providers • $4B+ in revenues • 10+ hospitals, long-term care facilities, physician offices, retail clinics and pharmacies, and rehabilitation centers services
  • 14. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved Cardinal Health 36th Annual JP Morgan Healthcare Conference Mike Kaufmann Chief Executive Officer Monday, January 8, 2018
  • 15. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. 1For more information on these measures, refer to the Use of Non-GAAP Financial Measures and Definitions schedules 2Attributable to Cardinal Health, Inc. 3GAAP diluted EPS for the twelve months ended June 30, 2017 compared to the prior year period was favorably impacted by $0.39, which includes $0.26 due to change in the effective tax rate and $0.13 due to the change in weighted average shares outstanding. The change in GAAP diluted EPS due to the effective tax rate is calculated as ((GAAP Earnings before Income Taxes for the current period times (one minus the current period GAAP Effective Tax Rate)) minus (GAAP Earnings before Income Taxes for the current period times (one minus the prior period GAAP Effective Tax Rate))) divided by the current period weighted average shares outstanding. The change in GAAP diluted EPS due to the weighted average shares outstanding is calculated as (GAAP Net Earnings for the current period divided by the current period weighted average shares outstanding) minus (GAAP Net Earnings for the current period divided by the prior period weighted average shares outstanding). 4Non-GAAP diluted EPS for the twelve months ended June 30, 2017 compared to the prior year period was favorably impacted by $0.44, which includes $0.27 due to change in the effective tax rate and $0.17 due to the change in weighted average shares outstanding. The change in Non-GAAP diluted EPS due to the effective tax rate is calculated as ((Non-GAAP Earnings before Income Taxes for the current period times (one minus the current period Non-GAAP Effective Tax Rate)) minus (Non-GAAP Earnings before Income Tax for the current period times (one minus the prior period Non-GAAP Effective Tax Rate))) divided by the current period weighted average shares outstanding. The change in Non-GAAP diluted EPS due to the weighted average shares outstanding is calculated as (Non-GAAP Net Earnings for the current period divided by the current period weighted average shares outstanding) minus (Non-GAAP Net Earnings for the current period divided by the prior period weighted average shares outstanding). The sum of the components may not equal the total due to rounding. We generally apply varying tax rates depending on the item’s nature and tax jurisdiction where it is incurred. There were no losses on extinguishment of debt during the periods presented. Operating Provision for Net Diluted Operating Earnings Earnings Before Income Net Earnings2 Diluted EPS2 Earnings Growth Rate Income Taxes Taxes Earnings2 Growth Rate EPS2 Growth Rate (in millions, except per common share amounts) GAAP 2,120$ (14)% 1,924$ 630$ 1,288$ (10)% 4.03$ (7)% Restructuring and employee severance 56 56 20 36 0.11 Amortization and other acquisition-related costs 527 527 165 362 1.13 Impairments and (gain)/loss on disposal of assets 18 18 6 12 0.04 Litigation (recoveries)/charges, net 48 48 19 29 0.09 Loss on extinguishment of debt - - - - - Non-GAAP 2,769$ (4)% 2,572$ 839$ 1,727$ (0)% 5.40$ 3 % GAAP 2,459$ 14 % 2,276$ 845$ 1,427$ 18 % 4.32$ 20 % LIFO charges/(credits) - - - - - Restructuring and employee severance 25 25 9 16 0.05 Amortization and other acquisition-related costs 459 459 143 316 0.96 Impairments and (gain)/loss on disposal of assets 21 21 6 15 0.04 Litigation (recoveries)/charges, net (69) (69) (27) (42) (0.13) Non-GAAP 2,895$ 17 % 2,711$ 976$ 1,732$ 18 % 5.24$ 20 % Fiscal Year 2016 Cardinal Health, Inc. and Subsidiaries GAAP / Non-GAAP Reconciliation1 Fiscal Year 2017
  • 16. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. 1For more information on these measures, refer to the Use of Non-GAAP Financial Measures and Definitions schedules 2Attributable to Cardinal Health, Inc. The sum of the components may not equal the total due to rounding. We generally apply varying tax rates depending on the item’s nature and tax jurisdiction where it is incurred. There were no losses on extinguishment of debt during the First Quarter 2017. Operating Provision for Net Diluted Operating Earnings Earnings Before Income Net Earnings2 Diluted EPS2 Earnings Growth Rate Income Taxes Taxes Earnings2 Growth Rate EPS2 Growth Rate (in millions, except per common share amounts) GAAP 262$ (51)% 178$ 61$ 115$ (63)% 0.36$ (63)% Restructuring and employee severance 132 132 47 85 0.27 Amortization and other acquisition-related costs 183 183 58 125 0.40 Impairments and (gain)/loss on disposal of assets 1 1 - 1 - Litigation (recoveries)/charges, net 32 32 13 19 0.06 Loss on extinguishment of debt - 1 1 - - Non-GAAP 610$ (9)% 527$ 180$ 346$ (13)% 1.09$ (12)% GAAP 535$ (14)% 494$ 184$ 309$ (19)% 0.96$ (17)% Restructuring and employee severance 9 9 4 5 0.02 Amortization and other acquisition-related costs 122 122 40 82 0.25 Impairments and (gain)/loss on disposal of assets 3 3 1 2 0.01 Litigation (recoveries)/charges, net 1 1 - 1 - Non-GAAP 669$ (9)% 629$ 229$ 399$ (13)% 1.24$ (10)% Cardinal Health, Inc. and Subsidiaries GAAP / Non-GAAP Reconciliation1 First Quarter 2018 First Quarter 2017
  • 17. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. Cardinal Health, Inc. and Subsidiaries Forward Looking non-GAAP Measures In this presentation, the Company presents forward-looking non-GAAP EPS and may present forward-looking non-GAAP ETR metrics. The Company does not provide EPS or ETR outlook, which are the most directly comparable GAAP measure to non-GAAP EPS and non-GAAP ETR, respectively, because changes in the items that the Company excludes from these non-GAAP measures can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of the Company’s routine operating activities. Additionally, due to their unpredictability, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on an EPS or ETR outlook. The timing and amount of any of the excluded items could significantly impact the actual EPS and ETR metrics. Over the past five fiscal years, the excluded items have lowered the Company’s EPS from $0.47 to $2.76, which includes a goodwill impairment charge of $2.32 per share related to our Nuclear Pharmacy Services division that we recognized in fiscal 2013.
  • 18. © Copyright 2018, Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. 1 The inventories of the Company's core pharmaceutical distribution facilities in the Pharmaceutical segment are valued at the lower of cost, using the LIFO method, or market. These charges or credits are included in cost of products sold, and represent changes in the Company's LIFO inventory reserve. 2 Programs by which the Company fundamentally changes its operations such as closing and consolidating facilities, moving manufacturing of a product to another location, production or business process sourcing, employee severance (including rationalizing headcount or other significant changes in personnel), and realigning operations (including realignment of the management structure of a business unit in response to changing market conditions). 3 Costs that consist primarily of amortization of acquisition-related intangible assets, transaction costs, integration costs, and changes in the fair value of contingent consideration obligations. 4 Asset impairments and (gains)/losses from the disposal of assets not eligible to be classified as discontinued operations are classified within impairments and (gain)/loss on disposal of assets within the condensed consolidated statements of earnings. 5 Loss contingencies related to litigation and regulatory matters and income from favorable resolution of legal matters. 6 Charges related to the make-whole premium on the redemption of notes. Cardinal Health, Inc. and Subsidiaries Definitions Debt: long-term obligations plus short-term borrowings. Debt to Total Capital: debt divided by (debt plus total Cardinal Health, Inc. shareholders’ equity). Interest and Other, net: other (income)/expense, net plus interest expense, net. Net Debt: a Non-GAAP measure defined as debt minus (cash and equivalents). Net Debt to Capital: a Non-GAAP measure defined as net debt divided by (net debt plus total Cardinal Health, Inc. shareholders’ equity). Non-GAAP Diluted EPS attributable to Cardinal Health, Inc. or "Non-GAAP Diluted EPS" or "Non-GAAP Diluted Earnings Per Share": non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding. Non-GAAP Diluted EPS from continuing operations: non-GAAP earnings from continuing operations divided by diluted weighted-average shares outstanding. Non-GAAP Effective Tax Rate: (provision for income taxes adjusted for (1) LIFO charges/(credits) 1 , (2) restructuring and employee severance 2 , (3) amortization and other acquisition-related costs 3 , (4) impairments and (gain)/loss on disposal of assets 4 , (5) litigation (recoveries)/charges, net 5 , and (6) loss on extinguishment of debt 6 ) divided by (earnings before income taxes adjusted for the same six items). Non-GAAP Gross Margin: Gross margin excluding LIFO charges/(credits).